Prednisolone sod phosphate

Posted: Qwe Date of post: 17-Feb-2019
Oz. <i>Prednisolone</i> <i>Sod</i> <i>Phosphate</i> OSHi-techbaserev3

Oz. Prednisolone Sod Phosphate OSHi-techbaserev3

Severe inflammation; immunosuppression Adults: Dosage individualized based on diagnosis, severity of condition, and response. Amphotericin B, mezlocillin, piperacillin, thiazide and loop diuretics, ticarcillin: additive hypokalemia Aspirin, other nonsteroidal anti-inflammatory drugs: increased risk of GI discomfort and bleeding Cardiac glycosides: increased risk of digitalis toxicity due to hypokalemia Cyclosporine: therapeutic benefits in organ transplant recipients, but with increased risk of toxicity Erythromycin, indinavir, itraconazole, ketoconazole, ritonavir, saquinavir: increased prednisone blood level and effects Hormonal contraceptives: impaired metabolism and increased effects of prednisone Isoniazid: decreased isoniazid blood level Live-virus vaccines: decreased antibody response to vaccine, increase risk of adverse effects Oral anticoagulants: reduced anticoagulant requirements, opposition to anticoagulant action Phenobarbital, phenytoin, rifampin: decreased prednisone efficacy Salicylates: reduced salicylate blood level Somatrem: inhibition of somatrem's growth-promoting effects Theophylline: altered pharmacologic effects of either drug Drug-diagnostic tests. CNS: headache, nervousness, depression, euphoria, personality changes, psychosis, vertigo, paresthesia, insomnia, restlessness, seizures, meningitis, increased intracranial pressure CV: hypotension, hypertension, vasculitis, heart failure, thrombophlebitis, thromboembolism, fat embolism, arrhythmias, shock EENT: posterior subcapsular cataracts (especially in children), glaucoma, nasal irritation and congestion, rebound congestion, sneezing, epistaxis, nasopharyngeal and oropharyngeal fungal infections, perforated nasal septum, anosmia, dysphonia, hoarseness, throat irritation (all with long-term use) GI: nausea, vomiting, abdominal distention, rectal bleeding, esophageal candidiasis, dry mouth, esophageal ulcer, pancreatitis, peptic ulcer GU: amenorrhea, irregular menses Hematologic: purpura Metabolic: sodium and fluid retention, hypokalemia, hypocalcemia, hyperglycemia, decreased carbohydrate tolerance, diabetes mellitus, growth retardation (in children), cushingoid effects (with long-term use), hypothalamic-pituitary-adrenal suppression (with systemic use longer than 5 days), adrenal suppression (with high-dose, long-term use) Musculoskeletal: muscle weakness or atrophy, myalgia, myopathy, osteoporosis, aseptic joint necrosis, spontaneous fractures (with long-term use), osteonecrosis, tendon rupture Respiratory: cough, wheezing, bronchospasm Skin: rash, pruritus, contact dermatitis, acne, striae, poor wound healing, hirsutism, thin fragile skin, petechiae, bruising, subcutaneous fat atrophy, urticaria, angioedema Other: bad taste, increased or decreased appetite, weight gain (with long-term use), facial edema, aggravation or masking of infections, hypersensitivity reaction Drug-drug. • Hypersensitivity to drug, other corticosteroids, alcohol, bisulfite, or tartrazine (with some products) • Systemic fungal infections • Live-virus vaccines (with immunosuppressant doses) • Active untreated infections (except in selected meningitis patients) Use cautiously in: • diabetes mellitus, glaucoma, renal or hepatic disease, hypothyroidism, cirrhosis, diverticulitis, nonspecific ulcerative colitis, recent intestinal anastomoses, inflammatory bowel disease, thromboembolic disorders, seizures, myasthenia gravis, heart failure, hypertension, osteoporosis, hypothyroidism, ocular herpes simplex, immunosuppression, emotional instability • pregnant or breastfeeding patients • children under age 6. Calcium, potassium, thyroid I uptake, thyroxine, triiodothyronine: decreased levels Cholesterol, glucose: increased levels Nitroblue tetrazolium test for bacterial infection: false-negative result Drug-herbs. Alfalfa: activation of quiescent systemic lupus erythematosus Echinacea: increased immune-stimulating effects Ephedra (ma huang): decreased drug blood level Ginseng: potentiation of immunomodulating effect Licorice: prolonged drug activity Drug-behaviors. Alcohol use: increased risk of gastric irritation and GI ulcers Check for signs and symptoms of depression and psychosis. • Assess blood glucose level carefully in diabetic patient. *Please see Dosage and Administration in full Prescribing Information because it should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient. In pediatric patients, the initial dose of prednisolone sodium phosphate oral solution (25 mg prednisolone per 5 m L) may vary depending on the specific disease entity being treated. The range of initial doses is 0.14 to 2 mg/kg/day in three or four divided doses (4 to 60 mg/m2bsa/day). Please see Dosage and Administration in full Prescribing Information because it should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient.

Minims <strong>Prednisolone</strong> <strong>Sodium</strong> <strong>Phosphate</strong> 0.5% w/v, Eye drops solution.

Minims Prednisolone Sodium Phosphate 0.5% w/v, Eye drops solution.

Use is contraindicated in viral, fungal, tuberculous and other bacterial infections. Prolonged application to the eye of preparations containing corticosteroids has caused increased intraocular pressure and therefore the drops should not be used in patients with glaucoma. In children, long-term, continuous topical corticosteroid therapy should be avoided due to possible adrenal suppression. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Care should be taken to ensure that the eye is not infected before Minims Prednisolone is used. Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following the instillation of the drops. (This blocks the passage of drops via the naso-lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa. Visual disturbance may be reported with systemic and topical corticosteroid use. Prednisolone sodium phosphate belongs to the family of medications called corticosteroids and is used for its ability to reduce inflammation in many parts of the body. Prednisolone is most often used to treat conditions involving swelling and itching (e.g., allergic reactions) and breathing problems that involve inflamed airways. Other uses include treatment of certain cancers and blood disorders or conditions where suppression of the immune system is needed. It may also be given when the body does not produce enough natural corticosteroids. This medication may be available under multiple brand names and/or in several different forms. Any specific brand name of this medication may not be available in all of the forms or approved for all of the conditions discussed here. As well, some forms of this medication may not be used for all of the conditions discussed here.

<i>Prednisolone</i> <i>Sodium</i> <i>Phosphate</i>- CAS Number 125-02-0
Prednisolone Sodium Phosphate- CAS Number 125-02-0

Achetez Prednisolone Sodium Phosphate - Numéro CAS 125-02-0 de LGC Standards. S'identifier ou s'enregistrer pour permettre l'achat de produits. Mylan manufactures PREDNISOLONE SODIUM PHOSPHATE Orally Disintegrating Tablets Orapred ODT in strengths of 10 mg15 mg30 mg.

Prednisolone sod phosphate
Rating 4,3 stars - 407 reviews